Wrapmanager Inc. Sells 7,874 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Wrapmanager Inc. lowered its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 38.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,737 shares of the biopharmaceutical company’s stock after selling 7,874 shares during the period. Wrapmanager Inc.’s holdings in Amicus Therapeutics were worth $120,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in FOLD. Wellington Management Group LLP grew its position in shares of Amicus Therapeutics by 13.5% during the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock worth $255,936,000 after buying an additional 2,856,101 shares during the period. Point72 Asset Management L.P. bought a new position in Amicus Therapeutics during the third quarter worth $13,530,000. Rice Hall James & Associates LLC grew its holdings in Amicus Therapeutics by 41.0% in the fourth quarter. Rice Hall James & Associates LLC now owns 1,371,080 shares of the biopharmaceutical company’s stock worth $12,916,000 after purchasing an additional 398,942 shares during the period. Old West Investment Management LLC grew its holdings in Amicus Therapeutics by 617.2% in the third quarter. Old West Investment Management LLC now owns 340,441 shares of the biopharmaceutical company’s stock worth $3,636,000 after purchasing an additional 292,976 shares during the period. Finally, PDT Partners LLC bought a new stake in Amicus Therapeutics in the third quarter valued at $2,702,000.

Amicus Therapeutics Stock Performance

Shares of Amicus Therapeutics stock opened at $9.11 on Wednesday. The company has a market cap of $2.80 billion, a PE ratio of -50.61, a price-to-earnings-growth ratio of 1.51 and a beta of 0.61. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. Amicus Therapeutics, Inc. has a 52 week low of $8.78 and a 52 week high of $14.02. The business has a 50 day moving average price of $9.53 and a 200-day moving average price of $10.39.

Insider Activity at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $10.02, for a total transaction of $75,150.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $8,884,273.08. The trade was a 0.84 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on FOLD shares. Guggenheim increased their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. StockNews.com cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. Wells Fargo & Company lowered their target price on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research report on Thursday, February 20th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.75.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.